<DOC>
	<DOC>NCT00328120</DOC>
	<brief_summary>The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer</brief_summary>
	<brief_title>Faslodex 500mg Multiple Dose Tolerability Study in BC Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Provision of written informed consent Postmenopausal woman who fulfils any one of the following criteria: Histological or cytological confirmation of breast cancer Estrogen receptor positive (ER+) or progesterone receptor positive (PgR+). Having received any one of the following therapy for advanced or recurrent breast cancer 2 or more regimens of hormonal therapy or immunotherapy or 2 or more regimens of chemotherapy, etc</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Faslodex</keyword>
</DOC>